DE1906743A1 - Mittel fuer die Diagnose von Vitamin-B12-Mangel und gegebenenfalls Folsaeuremangel und Verfahren zu dessen Anwendung - Google Patents
Mittel fuer die Diagnose von Vitamin-B12-Mangel und gegebenenfalls Folsaeuremangel und Verfahren zu dessen AnwendungInfo
- Publication number
- DE1906743A1 DE1906743A1 DE19691906743 DE1906743A DE1906743A1 DE 1906743 A1 DE1906743 A1 DE 1906743A1 DE 19691906743 DE19691906743 DE 19691906743 DE 1906743 A DE1906743 A DE 1906743A DE 1906743 A1 DE1906743 A1 DE 1906743A1
- Authority
- DE
- Germany
- Prior art keywords
- deficiency
- histidine
- acid
- urine
- loading
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 55
- 206010016880 Folate deficiency Diseases 0.000 title claims description 10
- 208000010188 Folic Acid Deficiency Diseases 0.000 title claims description 9
- 208000002670 vitamin B12 deficiency Diseases 0.000 title description 5
- 210000002700 urine Anatomy 0.000 claims description 75
- ZIYVHBGGAOATLY-UHFFFAOYSA-N methylmalonic acid Chemical compound OC(=O)C(C)C(O)=O ZIYVHBGGAOATLY-UHFFFAOYSA-N 0.000 claims description 58
- 239000002253 acid Substances 0.000 claims description 47
- 229960002885 histidine Drugs 0.000 claims description 45
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 39
- 230000007812 deficiency Effects 0.000 claims description 39
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 33
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 21
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 20
- 229960004295 valine Drugs 0.000 claims description 19
- 239000004473 Threonine Substances 0.000 claims description 18
- 229960002898 threonine Drugs 0.000 claims description 18
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 16
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 12
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 12
- 230000037396 body weight Effects 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 229960000310 isoleucine Drugs 0.000 claims description 9
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 231100000252 nontoxic Toxicity 0.000 claims description 5
- 230000003000 nontoxic effect Effects 0.000 claims description 5
- 229940113082 thymine Drugs 0.000 claims description 5
- 238000002405 diagnostic procedure Methods 0.000 claims description 4
- -1 halide salts Chemical class 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229930182844 L-isoleucine Natural products 0.000 claims description 3
- UKAUYVFTDYCKQA-UHFFFAOYSA-N homoserine Chemical compound OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims description 2
- 229940045999 vitamin b 12 Drugs 0.000 claims description 2
- CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical group O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 claims 1
- 229930182558 Sterol Natural products 0.000 claims 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 claims 1
- 150000003432 sterols Chemical class 0.000 claims 1
- 235000003702 sterols Nutrition 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical class C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 29
- 230000029142 excretion Effects 0.000 description 28
- 238000012360 testing method Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 208000007502 anemia Diseases 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 14
- 238000003745 diagnosis Methods 0.000 description 14
- 235000019152 folic acid Nutrition 0.000 description 14
- 239000011724 folic acid Substances 0.000 description 14
- 229960000304 folic acid Drugs 0.000 description 14
- 239000004474 valine Substances 0.000 description 14
- 210000003743 erythrocyte Anatomy 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 239000011347 resin Substances 0.000 description 12
- 229920005989 resin Polymers 0.000 description 12
- 229940088594 vitamin Drugs 0.000 description 12
- 229930003231 vitamin Natural products 0.000 description 12
- 235000013343 vitamin Nutrition 0.000 description 12
- 239000011782 vitamin Substances 0.000 description 12
- 229930003270 Vitamin B Natural products 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 208000011580 syndromic disease Diseases 0.000 description 11
- 235000019156 vitamin B Nutrition 0.000 description 11
- 239000011720 vitamin B Substances 0.000 description 11
- 150000003722 vitamin derivatives Chemical class 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- NRXIKWMTVXPVEF-BYPYZUCNSA-N N-formimidoyl-L-glutamic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC=N NRXIKWMTVXPVEF-BYPYZUCNSA-N 0.000 description 7
- 208000031845 Pernicious anaemia Diseases 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 102000001554 Hemoglobins Human genes 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000009102 absorption Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 235000015197 apple juice Nutrition 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 239000008351 acetate buffer Substances 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000003748 differential diagnosis Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000011121 sodium hydroxide Nutrition 0.000 description 4
- 230000036325 urinary excretion Effects 0.000 description 4
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000002906 microbiologic effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- 102100036486 Cobalamin binding intrinsic factor Human genes 0.000 description 2
- 101710123904 Cobalamin binding intrinsic factor Proteins 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 206010033546 Pallor Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000036654 deficiency anemia Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical group [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 238000003822 preparative gas chromatography Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- AYYQWADKKCDAHB-VKHMYHEASA-N (2s)-2-diazenylpentanedioic acid Chemical compound OC(=O)CC[C@H](N=N)C(O)=O AYYQWADKKCDAHB-VKHMYHEASA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241001501536 Alethe Species 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 101100016398 Danio rerio hars gene Proteins 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000289619 Macropodidae Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- IZNYFPZUWDUTDQ-UHFFFAOYSA-N OC(=O)C(C)C(O)=O.OC(=O)C(C)C(O)=O Chemical compound OC(=O)C(C)C(O)=O.OC(=O)C(C)C(O)=O IZNYFPZUWDUTDQ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- 102000006463 Talin Human genes 0.000 description 1
- 108010083809 Talin Proteins 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- NNBFNNNWANBMTI-UHFFFAOYSA-M brilliant green Chemical compound OS([O-])(=O)=O.C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 NNBFNNNWANBMTI-UHFFFAOYSA-M 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 150000001867 cobalamins Chemical class 0.000 description 1
- 229940010007 cobalamins Drugs 0.000 description 1
- 150000001869 cobalt compounds Chemical class 0.000 description 1
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 150000001918 cyanocobalamins Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000008049 diazo compounds Chemical class 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000005264 electron capture Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- PSFDQSOCUJVVGF-UHFFFAOYSA-N harman Chemical compound C12=CC=CC=C2NC2=C1C=CN=C2C PSFDQSOCUJVVGF-UHFFFAOYSA-N 0.000 description 1
- 150000002438 hydroxocobalamins Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100001017 macrocytic megaloblastic anemia Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 108010040003 polyglutamine Proteins 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 125000003011 styrenyl group Chemical group [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/20—Oxygen containing
- Y10T436/200833—Carbonyl, ether, aldehyde or ketone containing
- Y10T436/201666—Carboxylic acid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
- Y10T436/255—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.] including use of a solid sorbent, semipermeable membrane, or liquid extraction
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70730368A | 1968-02-21 | 1968-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1906743A1 true DE1906743A1 (de) | 1970-05-14 |
Family
ID=24841161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19691906743 Pending DE1906743A1 (de) | 1968-02-21 | 1969-02-11 | Mittel fuer die Diagnose von Vitamin-B12-Mangel und gegebenenfalls Folsaeuremangel und Verfahren zu dessen Anwendung |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US3577511A (enEXAMPLES) |
| BE (1) | BE728191A (enEXAMPLES) |
| BR (1) | BR6906347D0 (enEXAMPLES) |
| CH (1) | CH513638A (enEXAMPLES) |
| DE (1) | DE1906743A1 (enEXAMPLES) |
| ES (1) | ES363611A1 (enEXAMPLES) |
| FR (1) | FR2002311A1 (enEXAMPLES) |
| GB (1) | GB1219884A (enEXAMPLES) |
| IE (1) | IE33039B1 (enEXAMPLES) |
| IL (1) | IL31480A (enEXAMPLES) |
| NL (1) | NL6902675A (enEXAMPLES) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0269352A3 (en) * | 1986-11-20 | 1988-07-06 | Robert H. Allen | Assay for sulfhydryl amino acids and methods for detecting and distinguishing cobalamin and folic acid deficiency |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2803154C2 (de) * | 1977-01-27 | 1986-07-24 | Becton, Dickinson and Co., Paramus, N.J. | Gleichzeitige Radiountersuchung von Folat und Vitamin B 12 |
-
1968
- 1968-02-21 US US707303A patent/US3577511A/en not_active Expired - Lifetime
-
1969
- 1969-01-23 IL IL31480A patent/IL31480A/xx unknown
- 1969-01-24 IE IE98/69A patent/IE33039B1/xx unknown
- 1969-01-31 GB GB5435/69A patent/GB1219884A/en not_active Expired
- 1969-02-10 BE BE728191D patent/BE728191A/xx unknown
- 1969-02-11 DE DE19691906743 patent/DE1906743A1/de active Pending
- 1969-02-12 BR BR206347/69A patent/BR6906347D0/pt unknown
- 1969-02-13 ES ES363611A patent/ES363611A1/es not_active Expired
- 1969-02-17 FR FR6903907A patent/FR2002311A1/fr not_active Withdrawn
- 1969-02-20 NL NL6902675A patent/NL6902675A/xx unknown
- 1969-02-21 CH CH265969A patent/CH513638A/de not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0269352A3 (en) * | 1986-11-20 | 1988-07-06 | Robert H. Allen | Assay for sulfhydryl amino acids and methods for detecting and distinguishing cobalamin and folic acid deficiency |
Also Published As
| Publication number | Publication date |
|---|---|
| BR6906347D0 (pt) | 1973-02-13 |
| FR2002311A1 (fr) | 1969-10-17 |
| CH513638A (de) | 1971-10-15 |
| IE33039B1 (en) | 1974-03-06 |
| IE33039L (en) | 1969-08-21 |
| BE728191A (enEXAMPLES) | 1969-07-16 |
| NL6902675A (enEXAMPLES) | 1969-08-25 |
| GB1219884A (en) | 1971-01-20 |
| ES363611A1 (es) | 1971-02-01 |
| IL31480A (en) | 1974-03-14 |
| IL31480A0 (en) | 1969-03-27 |
| US3577511A (en) | 1971-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69227380T3 (de) | Verfahren zur bestimmung und behandlung von alzheimer-krankheit | |
| DE3686362T2 (de) | Verfahren zur behandlung von magen-darmstoerungen. | |
| DE3784852T2 (de) | Test fuer sulfhydrylaminosaeure und verfahren zum nachweis und zur unterscheidung von cobalamin und folsaeure. | |
| DE60128249T2 (de) | Verfahren zur diagnose von immunologischer lebensmittelsensitivität | |
| JP4520033B2 (ja) | 薬草抽出物の化学的および薬理学的標準化 | |
| DE2648458C2 (de) | Verfahren zum Nachweis eines im Serum von Krebspatienten vorkommenden, spezifischen Proteins und Reagenz zur Durchführung dieses Verfahrens | |
| DE2822546A1 (de) | Gallensaeuren-bindemittel | |
| EP0699442B1 (de) | Die verwendung eines stammes des pilzes fusarium zur herstellung von substanzen und eine darauf basierende zubereitung mit adaptiven und immunmodulierenden eigenschaften | |
| EP1904082B1 (de) | VERFAHREN ZUR BESTIMMUNG DER KONZENTRATION DER ADIPOZYTAREN FORM DES FATTY ACID BINDUNG PROTEIN (A-FABP, FABP4, aP2) | |
| DE60217351T3 (de) | Verfahren zur identifizierung von proben eines säugetiers als auch ein kit zur durchführung des verfahrens | |
| DE69730479T2 (de) | Marker und immunologisches Reagens für Dialyse verbundenen Amyloidosis, Diabetes Mellitus und Diabetes Mellitus-Komplikationen | |
| DE69033511T2 (de) | Verfahren zum Nachweis von Knochen- und anderen Bindegewebeerkrankungen in Menschen und Tieren | |
| DE60033420T2 (de) | Verfahren zur Quantifizierung von oxidiertem Glutathion | |
| DE69214843T2 (de) | Verfahren zum nachweis von beschädigungen des magenepithels | |
| DE202005020939U1 (de) | Kit zur Messung der Aktivierung neutrophiler Zellen | |
| DE69017673T2 (de) | Verminderung von post-prandial grossen neutralen aminosäureplasmakonzentrationen. | |
| DE2256331A1 (de) | Verfahren zur harnsaeurebestimmung | |
| DE2840760A1 (de) | Verfahren und reagens zum nachweis von kanzerogenen und antikanzerogenen substanzen | |
| DE1906743A1 (de) | Mittel fuer die Diagnose von Vitamin-B12-Mangel und gegebenenfalls Folsaeuremangel und Verfahren zu dessen Anwendung | |
| DE69628713T2 (de) | Marker und Reagenz für Diabetes mellitus und Diabetes-mellitus-Komplikationen | |
| DE10060989B4 (de) | Verfahren zur Diagnose der Laktose-Intoleranz und Diagnosekit zur Durchführung des Verfahrens | |
| DE2850950B2 (de) | Verwendung von nativem oder thermisch modifiziertem Cytochrom c als Stabilisator für ein immunochemisches Meßreagens, immunochemisches Meflreagens sowie Pufferlösung zur Probenverdünnung bei immunchemischen Meßverfahren | |
| DE69024348T2 (de) | Verfahren zum nachweis des diabetischen zustandes | |
| DE69329148T2 (de) | Schnelle extraktion von ciguatoxin aus kontaminierten geweben | |
| EP0565903B1 (de) | Verfahren zur immunologischen Bestimmung eines oder mehrerer Analyten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SH | Request for examination between 03.10.1968 and 22.04.1971 |